albumin - publications

Predict more albumin - ligand interactions now!


1. Nanomedicine. 2012 Apr 25. [Epub ahead of print]

Human serum albumin coated lipid nanoparticles for delivery of siRNA to breast
cancer.

Piao L, Li H, Teng L, Yung BC, Sugimoto Y, Brueggemeier RW, Lee RJ.

Division of Pharmaceutics, College of Pharmacy, The Ohio State University,
Columbus, OH 43210.

Human serum albumin (HSA) coated lipid nanoparticles (HSA-LNPs) loaded with
phrGFP-targeted siRNA (HSA-LNPs-siRNA) were prepared and evaluated for gene
downregulation effect in phrGFP transfected breast cancer cells and the
corresponding xenograft tumor model. HSA-LNPs-siRNA were successfully prepared
with a particle size of 79.5±5.5 nm. In phrGFP transfected MCF-7 cells,
HSA-LNPs-siRNA significantly decreased cell fluorescence even in the presence of
FBS. Moreover, cell fluorescence and phrGFP mRNA expression were significantly
downregulated by HSA-LNPs-siRNA in phrGFP transfected MCF-7, MDA-MB-231 and
SK-BR-3 cells compared to control or HSA-LNPs-siRNA (scrambled). In phrGFP
transfected MCF-7 xenograft tumor model, tumor fluorescence was significantly
decreased after three times i.v. administration of HSA-LNPs-siRNA at a dose of 3
mg/kg compared to siRNA alone. HSA-LNPs-siRNA demonstrated a superior
pharmacokinetic profile compared to siRNA at dose of 1 mg/kg. These results show
that the novel non-viral carrier, HSA-LNPs, may be used for the delivery of siRNA
to breast cancer cells.

Copyright © 2012. Published by Elsevier Inc.

PMID: 22542825 [PubMed - as supplied by publisher]